疑似阿片类药物过量患者中新型阿片类物质N-哌啶基依托尼秦(etonitazepipne)的鉴定
该研究为正在进行的多中心前瞻性队列研究中的病例系列,2020年10月6日至2021年10月31日筛查1006例、412例符合纳入标准,其中新泽西州一个中心在2021年7月3天内发现3例(年龄33-55岁)疑似阿片过量患者生物样本中检出N-哌啶基依托尼秦。3例均接受纳洛酮后意识改善(2 mg鼻内、8 mg鼻内、0.08 mg静脉),其中2例因阿片毒性复发接受后续剂量(0.4-0.6 mg静脉);1例诊断肺炎并收入ICU,1例急诊离院,1例在急诊期间再次用药并因纳洛酮输注入院。均未出现器官损伤或后遗症。作者认为这代表新型硝嗪类阿片的局部暴发,公共卫生毒物监测应纳入该类合成化合物的常规检测。
要点
- 2021年7月新泽西州一个中心3天内3例疑似阿片过量患者检出N-哌啶基依托尼秦,年龄33-55岁。
- 3例均接受纳洛酮后意识改善,首剂分别为2 mg鼻内、8 mg鼻内、0.08 mg静脉。
- 2例因阿片毒性复发接受后续纳洛酮剂量0.4-0.6 mg静脉。
- 1例诊断肺炎收入ICU,1例急诊离院,1例急诊期间再次用药并因纳洛酮输注入院。
- 3例均未出现器官损伤或后遗症。
适用人群与场景
- 正在进行的多中心前瞻性队列研究中急性阿片过量患者,筛查1006例、412例符合纳入标准。
- 3例检出N-哌啶基依托尼秦的患者年龄33-55岁,来自新泽西州一个中心,时间为2021年7月3天内。
处置流程与药物剂量
- 3例均接受纳洛酮后意识改善,首剂分别为2 mg鼻内、8 mg鼻内、0.08 mg静脉。
- 2例因阿片毒性复发接受后续纳洛酮剂量0.4-0.6 mg静脉。
- 1例因急诊期间再次用药并需纳洛酮输注而入院。
红旗征与不能漏的情况
- 2例出现阿片毒性复发,需追加纳洛酮0.4-0.6 mg静脉。
- 1例在急诊期间再次用药,需纳洛酮输注并入院。
研究设计与关键结果
- 病例系列:2020年10月6日至2021年10月31日筛查1006例,412例符合纳入标准,3例(年龄33-55岁)在新泽西州一个中心2021年7月3天内检出N-哌啶基依托尼秦。
- 2例报告使用可卡因,1例报告使用海洛因和阿普唑仑。
- 3例均接受纳洛酮后意识改善(2 mg鼻内、8 mg鼻内、0.08 mg静脉),2例因阿片毒性复发接受后续剂量(0.4-0.6 mg静脉)。
- 1例诊断肺炎收入ICU,1例急诊离院,1例急诊期间再次用药并因纳洛酮输注入院;均未出现器官损伤或后遗症。
证据类型、等级与局限
- 证据类型:多中心前瞻性队列研究中的病例系列。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为这些病例代表新型硝嗪类阿片的局部暴发。
- 作者认为公共卫生毒物监测应纳入该类新兴合成化合物的常规检测。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Novel opioids in the illicit drug supply, such as the "nitazene" group of synthetic opioids, present an ongoing public health problem due to high potency and respiratory depressant effects. We describe three patients in whom N-piperidinyl etonitazene, a compound not previously reported in human exposure, was detected after suspected opioid overdose. Other substances that these patients tested for included fentanyl, cocaine, levamisole, phenacetin, benzoylecgonine, para-fluorofentanyl, presumptive heroin (tested as 6-monoacetylmorphine (6-MAM), morphine, and codeine), and tramadol.
METHODS: This is a case series of patients with acute opioid overdose enrolled in an ongoing multicenter prospective cohort study. Data collected included reported substance use, clinical course, naloxone dose and response, outcome, and analytes detected in biological samples.
RESULTS: Between October 6, 2020 and October 31, 2021, 1006 patients were screened and 412 met inclusion criteria. Of these, three patients (age 33-55) tested positive for N-piperidinyl etonitazene at one site in New Jersey over a period of three days in July 2021. Two patients reported the use of cocaine; one reported the use of heroin and alprazolam. All three patients received naloxone with improvement in their mental status (2 milligrams (mg) intranasally (IN); 8 mg IN; 0.08 mg intravenous (IV)). Two of three received subsequent doses for recurrence of opioid toxicity (0.4-0.6 mg IV). One patient was diagnosed with pneumonia and admitted to the intensive care unit, one was discharged from the Emergency Department (ED), and one used additional drug while in the ED and required admission for a naloxone infusion. None developed organ damage or sequelae.
CONCLUSION: These cases represent a local outbreak of a novel "nitazene" opioid. Public health toxicosurveillance should incorporate routine testing of this emerging class of synthetic compounds in the illicit drug supply.
参考来源
- Calello DP, Aldy K, Jefri M, et al. Identification of a novel opioid, N-piperidinyl etonitazene (etonitazepipne), in patients with suspected opioid overdose. Clin Toxicol (Phila). 2022. PMID: 35708103. doi:10.1080/15563650.2022.2084406
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。